CEL-SCI Corporation recently announced that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy, Multikine. The accrual and treatment phases of this Phase 3 study are complete. 928 patients are enrolled in the study, and are being followed-up as required by the study protocol. In addition, the company also recently announced that the study’s Independent Data Monitoring Committee (IDMC) completed its most recent review of the data from all 928 patients enrolled in the study, and recommended continuing the study as there was no evidence of any significant safety questions.…
Browsing: Uncategorized
TapImmune Inc., a Florida-based leading clinical-stage immuno-oncology company recently announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV200 for treating triple-negative breast cancer (TNBC). This study is designed to help determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine’s molecular target, folate receptor-alpha (FRa). FRa is a cancer cell biomarker that is highly correlated with disease recurrence. Regarding this announcement, Dr. Richard Kenney, Head of Clinical Development for TapImmune, stated, “We are pleased to complete enrollment in this study almost…
TapImmune (TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers has announced that it has amended the patient inclusion criteria for its Phase 2 clinical trial of their T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy. TapImmune has enrolled the first women under this amended study protocol, which increases the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence. TPIV200 targets the folate receptor…
Dorsey client Mayo Clinic and Cambridge, Massachusetts-based nference recently announced the formation of Qrativ. Qrativ will combine nference’s artificial intelligence (AI) knowledge synthesis platform with Mayo Clinic’s medical expertise and clinical data to discover and develop treatments for diseases with unmet medical need. This effort is being boosted by an $8.3 million Series A financing supported by Matrix Capital Management, Matrix Partners and Mayo Clinic. The new venture will work with drug companies to discover whether molecules researched for treatment of one disease can effectively treat other conditions. Qrativ is the latest in a series of complex joint ventures and…
Avant Diagnostics, Inc. (‘Avant’) (OTC: AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink proteomic biomarker platform announced positive clinical utility data, the confirmation of the clinical utility of the Theralink Pancreatic Cancer assay in an expanded 60 patient data study in distinguishing patients that will experience a 5-year survival outcome following standard of care treatment regimens, versus those likely to experience significantly worse outcomes. The initial 40 patient study set was presented at The International Symposium on Pancreas Cancer 2016. The Company is evaluating the commercial potential of this assay to assist physicians in making prescribing decisions, as…
In 2016, Chinese companies invested more than $44B in the United States. The amount of investment has been growing steadily since 2000, increasing substantially each coming year. Over the last 16 years, there were more than 110 deals between Chinese investors and U.S. healthcare companies totaling $3.9 billion, 20 of which occurred last year in 2016. There are several factors that can be attributed to the increased amount of investment from China into U.S. companies in the healthcare business. After China’s “go global” policy at the start of the 21st century, many investors responded to the government’s strong promotion of…
TapImmune Inc, a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers, announced that it has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC). The four-arm study is designed to determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine’s molecular target, folate receptor-alpha (FRa). The multi-center Phase 2 study continues to enroll women with stage I(T1c)-III TNBC who have completed initial surgery and radiation/chemotherapy, and who have not yet had a…
OncoSec Medical Incorporated (NASDAQ: ONCS) was recently granted FDA Fast Track designation to address the large population of non-responders to the current leading checkpoint inhibitor therapies for stage 4 melanoma. The leading drugs in this $5 billion market are marketed under the names, Opdivo and Keytruda. An estimated 70% of patients do not respond to these checkpoint therapies. OncoSec has shown data indicating that when used with their technology ImmunoPulse IL-12, there is a 48% response in this non-responder patient population. Approximately 10,000 patients each year could be candidates for OncoSec’s ImmunoPulse IL-12 when used in combination with Opdivo…